No quarterly revenue total was found in Turn Therapeutics Inc.'s SEC filings.
Turn Therapeutics Inc. (TTRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $9.9 million in cash and investments and $7.3 million in total debt.
Revenue
—
Net income
$-5.85M
-502.5% vs prior quarter
Operating cash flow
$-923,364
+43.4% vs prior quarter
Free cash flow
—
EPS
$-0.20
-566.7% vs prior quarter
Dividend per share
None
Shares outstanding
29.79M
+0.0% vs prior quarter
Net cash
$2.63M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TTRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westlake Village, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2023016
- Former names
- Global Health Solutions, Inc (until Sep 30, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|
| Operating income | -$1.6M | -$1.2M | -$2.2M | -$1.9M |
| Net income | -$5.8M | -$970,972 | $279,070 | -$1.9M |
| Diluted EPS | -$0.20 | -$0.03 | $0.01 | -$0.07 |
| Operating cash flow | -$923,364 | -$1.6M | -$1.2M | -$1.4M |
| Total assets | $17.0M | $18.6M | $12.2M | $4.3M |
| Total liabilities | $16.3M | $12.5M | $7.5M | $3.8M |
| Stockholders' equity | $686,888 | $6.1M | $4.7M | $504,019 |
| Cash and investments | $9.9M | $11.0M | $4.0M | $513,695 |
| Total debt | $7.3M | $7.3M | $80,376 | $91,173 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Oct 19, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 7, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 10, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Aug 18, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 17, 2026 | Aug 14, 2026 |
All 122 Turn Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.